Conformational constraints in NAD analogs: Implications for dehydrogenase binding and specificity

Advances in Enzyme Regulation

Volumn 40, Issue 1, 2000, Pages 405-426

  Goldstein, Barry M ^a   Colby, Thomas D ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL DEHYDROGENASE; DRUG DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE; OXIDOREDUCTASE;

ANIMAL; BINDING AFFINITY; BINDING KINETICS; CHEMISTRY; CONFERENCE PAPER; CYCLIZATION; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME CONFORMATION; ENZYME SPECIFICITY; HUMAN; LIGAND BINDING; METABOLISM; MOLECULAR INTERACTION; PROTEIN BINDING; PROTEIN CONFORMATION; STEREOCHEMISTRY;

ANIMALS; HUMANS; NAD; OXIDOREDUCTASES; PROTEIN BINDING; PROTEIN CONFORMATION; SUBSTRATE SPECIFICITY;

ANIMALIA;

EID: 0034084310     PISSN: 00652571     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0065-2571(99)00056-4     Document Type: Article

References (90)

1. P. BAMBOROUGH and F. E. COHEN, Modeling protein-ligand complexes, Curr. Opin. Struct. Biol. 6, 236-241 (1996).
2. J. P. BOWEN, P. S. CHARIFSON, P. C. FOX, M. KONTOYIANNI, A. B. MILLER, D. SCHNUR, E. L. STEWART and C. VAN DYKE, Computer-assisted molecular modeling: indispensable tools for molecular pharmacology, J. Clin. Pharmacol. 33, 1149-1164 (1993).
3. T. J. MARRONE, J. M. BRIGGS and J. A. MCCAMMON, Structure-based drug design: computational advances, Annu. Rev. Pharmacol. Toxicol. 37, 71-90 (1997).
4. G. V. NIKIFOROVICH, Computational molecular modeling in peptide drug design, Int. J. Pept. Protein. Res. 44, 513-531 (1994).
5. M. I. PAGE and W. P. JENCKS, Entropic contributions to rate accelerations in enzymatic and intramolecular reactions and the chelate effect, Proc. Nat. Acad. Sci., USA 68, 1678-1683 (1971).
6. A. R. KHAN, J. C. PARRISH, M. E. FRASER, W. W. SMITH, P. A. BARTLETT and M. N. JAMES, Lowering the entropie barrier for binding conformationally flexible inhibitors to enzymes, Biochemistry 37, 16,839-16,845 (1998).
7. D. A. COONEY, H. N. JAYARAM, R. I. GLAZER, J. A. KELLEY, V. E. MARQUEZ, G. GEBEYEHU, A. C. VAN COTT, L. A. ZWELLING and D. G. JOHNS, Studies on the mechanism of action of tiazofurin metabolism to an analog of NAD with potent IMP dehydrogenase-inhibitory activity, Advan. Enzyme Regul. 21, 271-303 (1983).
8. T. J. BORITZKI, D. A. BERRY, J. A. BESSERER, P. D. COOK, D. W. FRY, W. R. LEOPOLD and R. C. JACKSON, Biochemical and antitumor activity of tiazofurin and its selenium analog (2-beta-D-ribofuranosyl-4-selenazolecarboxamide), Biochem. Pharmacol. 34, 1109-1114 (1985).
9. D. G. STREETER and R. K. ROBINS, Comparative in vitro studies of tiazofurin and a selenazole analog, Biochem. Biophys. Res. Commun. 115, 544-550 (1983).
10. V. E. MARQUEZ, C. K. TSENG, G. GEBEYEHU, D. A. COONEY, G. S. AHLUWALIA, J. A. KELLEY, M. DALAL, R. W. FULLER, Y. A. WILSON and D. G. JOHNS, Thiazole-4-carboxamide adenine dinucleotide (TAD). Analogues stable to phosphodiesterase hydrolysis, J. Med. Chem. 29, 1727-1731 (1986).
11. G. GEBEYEHU, V. E. MARQUEZ, A. VAN COTT, D. A. COONEY, J. A. KELLEY, H. N. JAYARAM, G. S. AHLUWALIA, R. L. DION, Y. A. WILSON and D. G. JOHNS, Ribavirin, tiazofurin, and selenazofurin: mononucleotides and nicotinamide adenine dinucleotide analogues. Synthesis, structure, and interactions with IMP dehydrogenase, J. Med. Chem. 28, 99-105 (1985).
12. L. HEDSTROM and C. C. WANG, Mycophenolic acid and thiazole adenine dinucleotide inhibition of Tritrichomonas foetus inosine 5′-monophosphate dehydrogenase: implications on enzyme mechanism, Biochemistry 29, 849-854 (1990).
13. T. D. COLBY, K. VANDERVEEN, M. D. STRICKLER, G. D. MARKHAM and B. M. GOLDSTEIN, Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design, Proc. Natl. Acad. Sci., USA 96, 3531-3536 (1999).
14. B. M. GOLDSTEIN, J. E. BELL and V. E. MARQUEZ, Dehydrogenase binding by cofactor analogs, Biochem. Soc. Trans. 16, 862-863 (1988).
15. K. GHAREHBAGHI, A. SREENATH, Z. HAO, K. D. PAULL, T. SZEKERES, D. A. COONEY, K. KROHN and H. N. JAYARAM, Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin, Biochem. Pharmacol. 48, 1413-1419 (1994).
16. P. FRANCHETTI, L. CAPPELLACCI, P. PERLINI, H. N. JAYARAM, A. BUTLER, B. P. SCHNEIDER, F. R. COLLART, E. HUBERMAN and M. GRIFANTINI, Isosteric analogues of nicotinamide adenine dinucleotide derived from furanfurin, thiophenfurin, and selenophenfurin as mammalian inosine monophosphate dehydrogenase (type I and II) inhibitors, J. Med. Chem. 41, 1702-1707 (1998).
17. G. WEBER, N. PRAJDA, M. ABONYI, K. Y. LOOK and G. TRICOT, Tiazofurin: molecular and clinical action, Anticancer Res. 16, 3313-3322 (1996).
18. J. C. WU, Mycophenolate mofetil: molecular mechanisms of action, Perspectives in Drug Discovery and Design 2, 185-204 (1994).
19. L. C. ANTONINO and J. C. WU, Human IMP dehydrogenase catalyzes the dehalogenation of 2-fluoro-and 2-chloroinosine 5′-monophosphate in the absence of NAD, Biochemistry 33, 1753-1759 (1994).
20. S. F. CARR, E. PAPP, J. C. WU and Y. NATSUMEDA, Characterization of human type I and type II IMP dehydrogenases, J. Biol. Chem. 268, 27,286-27,290 (1993).
21. M. L. PALL, GTP: A central regulator of cellular anabolism. (B. L. HORECKER and E. R. STADTMAN, eds.), Current Topics in Cellular Regulation. Vol. 25, Academic Press New York. pp. 1-20. 1985.
22. R. A. MANDANAS, D. S. LEIBOWITZ, K. GHAREHBAGHI, T. TAUCHI, G. S. BURGESS, K. MIYAZAWA, H. N. JAYARAM and H. S. BOSWELL, Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells, Blood 82, 1838-1847 (1993).
23. H. N. JAYARAM, R. L. DION, R. I. GLAZER, D. G. JOHNS, R. K. ROBINS, P. C. SRIVASTAVA and D. A. COONEY, Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193), Biochem. Pharmacol. 31, 2371-2380 (1982).
24. E. OLAH, B. CSOKAY, N. PRAJDA, Z. KOTE-JARAI, Y. A. YEH and G. WEBER, Molecular mechanisms in the antiproliferative action of taxol and tiazofurin, Anticancer Res. 16, 2469-2477 (1996).
25. M. VITALE, L. ZAMAI, E. FALCIERI, G. ZAULI, P. GOBBI, S. SANTI, C. CINTI and G. WEBER, IMP dehydrogenase inhibitor, tiazofurin, induces apoptosis in K562 human erythroleukemia cells, Cytometry 30, 61-66 (1997).
26. J. TOVARI, J. BOCSI, A. LADANYI, K. LAPIS and J. TIMAR, The antitumor effect of tiazofurin (TR) consists of anti-proliferative and anti-invasive elements, Anticancer Res. 16, 3307-3312 (1996).
27. K. Y. LAPIS, J. BOCSI, J. TOVARI, I. BARTHA, J. TIMAR and E. RASO, Antiinvasive effects of tiazofurin on liver-metastatic human colon carcinoma xenografts, Anticancer Res. 16, 3323-3331 (1996).
28. J. TIMAR, J. TOVARI, G. POGANY, A. LADANYI, S. PAKU, E. RSO, J. BOCSI, A. JENEY and K. LAPIS, The antimetabolite tiazofurin (TR) inhibits glycoconjugate biosynthesis and invasiveness of tumour cells, Eur. J. Cancer 32A, 152-159 (1996).
29. D. N. CARNEY, G. S. AHLUWALIA, H. N. JAYARAM, D. A. COONEY and D. G. JOHNS, Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells, J. Clin. Invest. 75, 175-182 (1985).
30. K. KIGUCHI, F. R. COLLART, C. HENNING-CHUBB and E. HUBERMAN, Cell differentiation and altered IMP dehydrogenase expression induced in human T-lymphoblastoid leukemia cells by mycophenolic acid and tiazofurin, Expr. Cell Res. 187, 47-53 (1990).
31. E. OLAH, Y. NATSUMEDA, T. IKEGAMI, Z. KOTE, M. HORANYI, J. SZELENYI, E. PAULIK, T. KREMMER, S. R. HOLLAN, J. SUGAR and G. WEBER, Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 leukemia cells, Proc. Natl. Acad. Sci., USA 85, 6533-6537 (1988).
32. Y. SIDI, E. BEERY, C. PANET, L. WASSERMAN, A. NOVOGRODSKY and J. NORDENBERG, Growth inhibition and induction of phenotypic alterations by tiazofurin: differential effects on MCF-7 breast cancer and HBL-100 breast cell lines, European J. Cancer Clin. Oncol. 25, 883-889 (1989).
33. J. A. SOKOLOSKI, J. LI, A. NIGAM and A. C. SARTORELLI, Induction of the differentiation of HL-60 and WEHI-3B D+ leukemia cells by lithium chloride, Leuk. Res. 17, 403-410 (1993).
34. M. FRITZER, K. GHAREHBAGHI, K. PILLWEIN, P. CHIBA, H. GOLDENBERG and T. SZEKERES, GM-CSF: modulation of biochemical and cytotoxic effect of tiazofurin in HL-60 cells, Brit. J. Haematol. 84, 552-554 (1993).
35. B. M. GOLDSTEIN, J. F. LEARY, B. A. FARLEY, V. E. MARQUEZ, P. C. LEVY and P. T. ROWLEY, Induction of HL60 cell differentiation by tiazofurin and its analogs: characterization and efficacy, Blood 78, 593-598 (1991).
36. F. R. COLLART and E. HUBERMAN, Expression of IMP dehydrogenase in differentiating HL-60 cells, Blood 75, 593-598 (1990).
37. R. D. KNIGHT, J. MANGUM, D. L. LUCAS, D. A. COONEY, E. C. KHAN and D. G. WRIGHT, Inosine monophosphate dehydrogenase and myeloid cell maturation, Blood 69, 634-639 (1987).
38. J. LALIBERTE, A. YEE, Y. XIONG and B. S. MITCHELL, Effects of guanine nucleotide depletion on cell cycle progression in human T lymphocytes, Blood 91, 2896-2904 (1998).
39. J. T. RANSOM, Mechanism of action of mycophenolate mofetil, Ther. Drug Monit. 17, 681-684 (1995).
40. B. S. MITCHELL, J. S. DAYTON, L. A. TURKA and C. B. THOMPSON, IMP dehydrogenase inhibitors as immunomodulators, Ann. NY Acad. Sci. 685, 217-224 (1993).
41. D. G. WRIGHT, M. S. BOOSALIS, K. WARASKA, L. J. OSHRY, L. R. WEINTRAUB and E. VOSBURGH, Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis, Anticancer Res. 16, 3349-3351 (1996).
42. G. TRICOT and G. WEBER, Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic graulocytic leukemia with tiazofurin, selective blocker of inosine 5′-phosphate dehydrogenase activity, Anticancer Res. 16, 3341-3347 (1996).
43. M. BEHREND, A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation, Clini. Nephrol. 45, 336-341 (1996).
44. L. M. SHAW, H. W. SOLLINGER, P. HALLORAN, R. E. MORRIS, R. W. YATSCOFF, J. RANSOM, I. TSINA, P. KEOWN, D. W. HOLT, R. LIEBERMAN, A. JAKLITSCH and J. POTTER, Mycophenolate mofetil: a report of the consensus panel, Ther. Drug Monit. 17, 690-699 (1995).
45. B. M. GOLDSTEIN and T. D. COLBY, IMP dehydrogenase: structural aspects of inhibitor binding, Current Med. Chem. 6, 519-536 (1999).
46. Y. NATSUMEDA, S. OHNO, H. KAWASAKI, Y. KONNO, G. WEBER and K. SUZUKI, Two distinct cDNAs for human IMP dehydrogenase, J. Biol. Chem. 265, 5292-5295 (1990).
47. Y. KONNO, Y. NATSUMEDA, M. NAGAI, Y. YAMAJI, S. OHNO, K. SUZUKI and G. WEBER, Expression of human IMP dehydrogenase types I and II in Escherichia coli and distribution in human normal lymphocytes and leukemic cell lines, J. Biol. Chem. 266, 506-509 (1991).
48. M. NAGAI, Y. NATSUMEDA, Y. KONNO, R. HOFFMAN, S. IRINO and G. WEBER, Selective up-regulation of type II inosine 5′-monophosphate dehydrogenase messenger RNA expression in human leukemias, Cancer Res. 51, 3886-3890 (1991).
49. B. M. GOLDSTEIN, F. TAKUSAGAWA and H. M. BERMAN, Structural studies of a new antitumor agent: tiazofurin and its inactive analogs, J. Am. Chem. Soc. 105, 7416-7422 (1983).
50. B. M. GOLDSTEIN, D. T. MAO and V. E. MARQUEZ, Ara-tiazofurin: conservation of structural features in an unusual thiazole nucleoside, J. Med. Chem. 31, 1026-1031 (1988).
51. F. T. BURLING, B. GABRIELSEN and B. M. GOLDSTEIN, Structures of the 2′,3′-dideoxy and 2′,3′-didehydro-2′,3′-dideoxy analogs of tiazofurin, Acta Crystallogr., Sect. C: Cryst. Struct. Commun. C47, 1272-1275 (1991).
52. F. T. BURLING, W. H. HALLOWS, M. J. PHELAN, B. GABRIELSEN and B. M. GOLDSTEIN, Structures of the 4-cyano and 4-methylamidate analogs of tiazofurin, Acta Crystallogr., Sect. B, Struct. Sci. 48, 677-683 (1992).
53. F. T. BURLING and B. M. GOLDSTEIN, Computational studies of nonbonded sulfur-oxygen and selenium-oxygen interactions in the thiazole and selenazole nucleosides, J. Am. Chem. Soc. 114, 2313-2320 (1992).
54. B. M. GOLDSTEIN, F. TAKUSAGAWA and H. W. BERMAN, Structural studies of a new antitumor and antiviral agent: selenazofurin and its alpha anomer, J. Am. Chem. Soc. 107, 1394-1400 (1985).
55. P. FRANCHETTI, L. CAPPELLACCI, G. A. SHEIKHA, H. N. JAYARAM, V. V. GURUDUTT, T. SINT, B. P. SCHNEIDER, W. D. JONES, B. M. GOLDSTEIN, G. PERRA, A. DE MONTIS, A. G. LOI, P. LA COLLA and M. GRIFANTINI, Synthesis, structure, and antiproliferative activity of selenophenfurin, an inosine 5′-monophosphate dehydrogenase inhibitor analogue of selenazofurin, J. Med. Chem. 40, 1731-1737 (1997).
56. P. FRANCHETTI, L. CAPPELLACCI, M. GRIFANTINI, A. BARZI, G. NOCENTINI, H. YANG, A. O'CONNOR, H. N. JAYARAM, C. CARRELL and B. M. GOLDSTEIN, Furanfurin and thiophenfurin: two novel tiazofurin analogues. Synthesis, structure, antitumor activity, and interactions with inosine monophosphate dehydrogenase, J. Med. Chem. 38, 3829-3837 (1995).
57. F. T. BURLING and B. M. GOLDSTEIN, A database study of nonbonded intramolecular sulfur-nucleophile contacts, Acta Crystallogr., Sect B, Struct. Sci. 49, 738-744 (1993).
58. B. M. GOLDSTEIN, S. D. KENNEDY and W. J. HENNEN, Selenium-77 NMR and crystallographic studies of selenazofurin and its 5-amino derivative, J. Am. Chem. Soc. 112, 8265-8268 (1990).
59. B. M. GOLDSTEIN, H. LI, W. H. HALLOWS, D. A. LANGS, P. FRANCHETTI, L. CAPPELLACCI and M. GRIFANTINI, C-glycosyl bond conformation in oxazofurin: crystallographic and computational studies of the oxazole analog of tiazofurin, J. Med. Chem. 37, 1684-1688 (1994).
60. D. H. R. BARTON, M. B. HALL, Z. LIN and S. I. PAREKH, Unusual attractive interactions between selenium and oxygen in selenoiminoquinones, J. Am. Chem. Soc. 115, 5056-5059 (1993).
61. 77Se NMR spectroscopy and natural bond orbital analysis, Chem. Commun. 2, 205-206 (1999).
62. G. M. MAKARA and G. M. KESERU, On the conformation of tiazofurin analogues, J. Med. Chem. 40, 4154-4159 (1997).
63. H. EKLUND, Structural studies of horse liver alcohol dehydrogenase: coenzyme, substrate and inhibitor binding, Pharmacol., Biochem. Behavior 18, 73-81 (1983).
64. H. EKLUND, Coenzyme binding in alcohol dehydrogenase, Biochem. Soc. Trans. 17, 293-296 (1989).
65. J. P. SAMAMA, E. ZEPPEZAUER, J. F. BIELLMANN and C. I. BRANDEN, The crystal structure of complexes between horse liver alcohol dehydrogenase and the coenzyme analogues 3-iodopyridine-adenine dinucleotide and pyridine-adenine dinucleotide, Eur. J. Biochem. 81, 403-409 (1977).
66. H. EKLUND, J. P. SAMAMA and T. A. JONES, Crystallographic investigations of nicotinamide adenine dinucleotide binding to horse liver alcohol dehydrogenase, Biochemistry 23, 5982-5996 (1984).
67. H. LI, W. H. HALLOWS, J. S. PUNZI, V. E. MARQUEZ, H. L. CARRELL, K. W. PANKIEWICZ, K. A. WATANABE and B. M. GOLDSTEIN, Crystallographic studies of two alcohol dehydrogenase-bound analogues of thiazole-4-carboxamide adenine dinucleotide (TAD), the active anabolite of the antitumor agent tiazofurin, Biochemistry 33, 23-32 (1994).
68. K. W. PANKIEWICZ, J. ZEIDLER, L. A. CISZEWSKI, J. E. BELL, B. M. GOLDSTEIN, H. N. JAYARAM and K. A. WATANABE, Synthesis of isosteric analogues of nicotinamide adenine dinucleotide containing C-nucleotide of nicotinamide or picolinamide, J. Med. Chem. 36, 1855-1859 (1993).
69. K. W. PANKIEWICZ, Novel nicotinamide adeninedinucleotide analogues as potential anticancer agents: quest for specific inhibition of inosine monophosphate dehydrogenase, Pharmacol. Therap. 76, 89-100 (1997).
70. K. KROHN, H. HEINS and K. WIELCKENS, Synthesis and cytotoxic activity of C-glycosidic nicotinamide riboside analogues, J. Med. Chem. 35, 511-517 (1992).
71. H. LI, W. H. HALLOWS, J. S. PUNZI, K. W. PANKIEWICZ, K. A. WATANABE and B. M. GOLDSTEIN, Crystallographic studies of isosteric NAD analogs bound to alcohol dehydrogenase: specificity and substrate binding in two ternary complexes, Biochemistry 33, 11,734-11,744 (1994).
72. B. J. BAHNSON, T. D. COLBY, J. K. CHIN, B. M. GOLDSTEIN and J. P. KLINMAN, A link between protein structure and enzyme catalyzed hydrogen tunneling, Proc. Natl. Acad. Sci., USA 94, 12,797-12,802 (1997).
73. T. D. COLBY, B. J. BAHNSON, J. K. CHIN, J. P. KLINMAN and B. M. GOLDSTEIN, Active site modifications in a double mutant of liver alcohol dehydrogenase: structural studies of two enzyme-ligand complexes, Biochemistry 37, 9295-9304 (1998).
74. B. M. GOLDSTEIN, H. LI, J. P. JONES and J. BELL, CNAD: a potent and specific inhibitor of alcohol dehydrogenase, J. Med. Chem. 37, 392-399 (1994).
75. K. W. PANKIEWICZ, K. LESIAK, A. ZATORSKI, B. M. GOLDSTEIN, S. F. CARR, M. SOCHACKI, A. MAJUMDAR, M. SEIDMAN and K. A. WATANABE, The practical synthesis of a methylenebisphosphonate analogue of benzamide adenine dinucleotide: inhibition of human inosine monophosphate dehydrogenase (type I and II), J. Med. Chem. 40, 1287-1291 (1997).
76. V. C. SEKHAR and B. V. PLAPP, Mechanism of binding of horse liver alcohol dehydrogenase and nicotinamide adenine dinucleotide, Biochemistry 27, 5082-5088 (1988).
77. M. LI, F. DYDA, I. BENHAR, I. PASTAN and D. DAVIES, Crystal structure of the catalytic domain of Pseudomonas exotoxin A complexed with a nicotinamide adenine dinucleotide analog: implications for the activation process and for ADP ribosylation, Proc. Natl. Acad. Sci., USA 93, 6902-6906 (1996).
78. W. WANG and L. HEDSTROM, Kinetic mechanism of human inosine 5′-monophosphate dehydrogenase type II: random addition of substrates and ordered release of products, Biochemistry 36, 8479-8483 (1997).
79. B. XIANG and G. D. MARKHAM, Probing the mechanism of inosine monophosphate dehydrogenase with kinetic isotope effects and NMR determination of the hydride transfer stereospecificity, Arch. Biochem. Biophys. 348, 378-382 (1997).
80. L. C. ANTONINO, K. STRAUB and J. C. WU, Probing the active site of human IMP dehydrogenase using halogenated purine riboside 5′-monophosphates and covalent modification reagents, Biochemistry 33, 1760-1765 (1994).
81. M. D. SINTCHAK, M. A. FLEMING, O. FUTER, S. A. RAYBUCK, S. P. CHAMBERS, P. R. CARON, M. A. MURCKO and K. P. WILSON, Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid, Cell 85, 921-930 (1996).
82. F. G. WHITBY, H. LUECKE, P. KUHN, J. R. SOMOZA, J. A. HUETE-PEREZ, J. D. PHILLIPS, C. P. HILL, R. J. FLETTERICK and C. C. WANG, Crystal structure of tritrichomonas foetus inosine-5′-monophosphate dehydrogenase and the enzyme-product complex, Biochemistry 36, 10,666-10,674 (1997).
83. R. ZHANG, G. EVANS, F. J. ROTELLA, E. M. WESTBROOK, D. BENO, E. HUBERMAN, A. JOACHIMIAK and F. R. COLLART, Characteristics and crystal structure of bacterial inosine-5′-monophosphate dehydrogenase, Biochemistry 38, 4691-4700 (1999).
84. P. C. SRIVASTAVA, G. R. REVANKAR and R. K. ROBINS, Synthesis and biological activity of nucleosides and nucleotides related to the antitumor agent 2-beta-D-ribofuranosylthiazole-4-carboxamide, J. Med. Chem. 27, 266-269 (1984).
85. C. SCHALK-HIHI, Y. Z. ZHANG and G. D. MARKHAM, The conformation of NADH bound to inosine 5′-monophosphate dehydrogenase determined by transferred nuclear Overhauser effect spectroscopy, Biochemistry 37, 7608-7616 (1998).
86. A. ZATORSKI, B. M. GOLDSTEIN, T. D. COLBY, J. P. JONES and K. W. PANKIEWICZ, Potent inhibitors of human inosine monophosphate dehydrogenase type II. Fluorine-substituted analogues of thiazole-4-carboxamide adenine dinucleotide, J. Med. Chem. 38, 1098-1105 (1995).
87. A. FERSHT, Enzyme Structure and Mechanism. W. H. Freeman and Co New York. 1985.
88. M. M. KABAT, K. W. PANKIEWICZ and K. A. WATANABE, Synthesis of 5-beta-D-ribofuranosylnicotinamide and its N-methyl derivative. The isosteric analogues of nicotinamide nucleoside, J. Med. Chem. 30, 924-927 (1987).
89. K. LESIAK, K. A. WATANABE, A. MAJUMDAR, J. POWELL, M. SEIDMAN, K. VANDERVEEN, B. M. GOLDSTEIN and K. W. PANKIEWICZ, Synthesis of a methylenebis(phosphonate) analogue of mycophenolic adenine dinucleotide: a glucuronidation-resistant MAD analogue of NAD, J. Med. Chem. 41, 618-622 (1998).
90. A. ZATORSKI, K. A. WATANABE, S. F. CARR, B. M. GOLDSTEIN and K. W. PANKIEWICZ, Chemical synthesis of benzamide adenine dinucleotide: inhibition of inosine monophosphate dehydrogenase (types I and II), J. Med. Chem. 39, 2422-2426 (1996).